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Abstract
Candidiasis are life-threatening systemic fungal diseases, especially of gastro intestinal track, skin and mucous membranes
lining various body cavities like the nostrils, the mouth, the lips, the eyelids, the ears or the genital area. Due to increasing
resistance of candidiasis to existing drugs, it is very important to look for new strategies helping the treatment of such
fungal diseases. One promising strategy is the use of the probiotic microorganisms, which when administered in adequate
amounts confer a health benefit. Such a probiotic microorganism is yeast Saccharomyces boulardii, a close relative of baker
yeast. Saccharomyces boulardii cells and their extract affect the virulence factors of the important human fungal pathogen C.
albicans, its hyphae formation, adhesion and biofilm development. Extract prepared from S. boulardii culture filtrate was
fractionated and GC-MS analysis showed that the active fraction contained, apart from 2-phenylethanol, caproic, caprylic
and capric acid whose presence was confirmed by ESI-MS analysis. Biological activity was tested on C. albicans using extract
and pure identified compounds. Our study demonstrated that this probiotic yeast secretes into the medium active
compounds reducing candidal virulence factors. The chief compound inhibiting filamentous C. albicans growth comparably
to S. boulardii extract was capric acid, which is thus responsible for inhibition of hyphae formation. It also reduced candidal
adhesion and biofilm formation, though three times less than the extract, which thus contains other factors suppressing C.
albicans adherence. The expression profile of selected genes associated with C. albicans virulence by real-time PCR showed
a reduced expression of HWP1, INO1 and CSH1 genes in C. albicans cells treated with capric acid and S. boulardii extract.
Hence capric acid secreted by S. boulardii is responsible for inhibition of C. albicans filamentation and partially also adhesion
and biofilm formation.
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Introduction
Saccharomyces boulardii (Biocodex, Gentilly, France) is a non-
pathogenic yeast used as a probiotic strain in prevention or
treatment of intestinal diseases, mainly different types of diarrhea
[1,2,3,4]. The activity of S. boulardii against enteric pathogens
involves many different mechanisms and can be caused either by
S. boulardii cells or by agents secreted by them, such as the 120 kDa
protein which inhibits cholera toxin-induced adenylate cyclase and
chloride secretion [5] or the 63 kDa phosphatase that exerts
dephosphorylation activity against LPS of entheropathogenic E.
coli [6], and a 54 kDa proteinase which degrades both Clostridium
difficile toxins A and B [7]. Moreover, S. boulardii stimulates the
activity of brush-border membrane enzymes implicated in nutrient
degradation and absorption possibly by the secreting polyamines
[8]. There are many investigations describing the effect of S.
boulardii on bacterial pathogens, but little is know about its
influence on yeast pathogen Candida albicans.
C. albicans is the most common opportunistic fungal pathogen
isolated from human body, causing both superficial and systemic
diseases. Infections develop often after antibiotic treatment, the
most serious being prevalent in immunocompromised patients [9].
The major virulence factor of C. albicans is the capacity to switch
between yeast, pseudohyphae and hyphae, important both for
tissue adhesion and invasion [10]. C. albicans strains locked into
either the yeast or filamentous form are less virulent [11,12]. C.
albicans virulence also depends on its ability to adhere to and form
biofilms on many surfaces, such as medical implants, intravascular
catheters, or host tissues [13,14] as well as secretion of enzymes
like secreted aspartyl proteinases and phospholipases that play
important role in tissue invasion [15,16].
Increasing resistance of C. albicans strains to antifungal agents
prompted higher interest in molecular mechanisms of its virulence
in search for new targets for therapy. Factors involved in hyphal
development may constitute such targets and agents inhibiting
formation of hyphae can lead to great improvements in antifungal
therapy. It is known that farnesol, a quorum sensing molecule
secreted by C. albicans itself, blocks the conversion of its yeast cells
to hyphae. Isoamyl alcohol, 2-phenylethanol and 1-dodecanol are
other compounds known to control morphological transformation
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fatty acids, has also been found to have similar activity [18]. Fatty
acids or their monoglyceride derivatives have long been known as
antimicrobial agents that kill Gram-positive and Gram-negative
bacteria. They also exhibit antiviral and antifungal activity.
Studies of Kabara et al. (1972)[19] revealed that lauric acid with
a 12 carbon chain is the most active among saturated fatty acids.
Ells et al. (2009) [20] reported that arachidonic acid increased
antifungal susceptibility of C. albicans biofilm. Furthermore, capric
acid and lauric acid were found to effectively kill C. albicans cells
[21]. Cle ´ment et al. (2006) [22] demonstrated the suppression of
candidal hyphae formation by whey-derived fatty acids, among
which the most active were lauric acid, myristoleic acid, linoleic
acid and arachidonic acid.
Recently, it was shown that S. boulardii decreases inflammatory
reaction and colonization of mouse intestine by the C. albicans
infection [23]. Moreover, intraepithelial lymphocytes infected by
E. coli and C. albicans were found to respond to the presence of S.
boulardii by decreasing IL-1b secretion [24]. Translocation of C.
albicans from the intestinal tract to the mesenteric lymph nodes
(MLN) and some organs was reduced after treatment with S.
boulardii [25].
We have previously shown that the presence of S. boulardii cells
and an extract from its culture filtrate inhibited C. albicans hyphae
formation, adhesion and biofilm formation on plastic surfaces
[26]. The present study was focused on the identification of
factors secreted by S. boulardii - fatty acids and 2-phenylethanol -
and analysis of their activities. We demonstrated the influence of
these factors on C. albicans ability to form hyphae and adhere to
plastic surfaces and examined which C. albicans genes, associated
with its virulence, are regulated by the exposure to capric acid
(C10:0).
Results and Discussion
We have previously shown that the presence of S. boulardii cells
inhibited yeast to hyphae switch of C. albicans. S. boulardii also
reduced C. albicans adhesion and subsequent biofilm formation on
plastic surfaces [26]. Not only S. boulardii cells were active, but also
an extract prepared from its culture filtrate exerted the same effect
against C. albicans, suggesting that S. boulardii secretes into the
medium active factor/s which are efficiently extracted into ethyl
acetate.
Determination of chemical structure of compounds
secreted by S. boulardii
In order to identify the active compound/s S. boulardii extract
was first partially separated using preparative TLC. The seven
collected fractions were then checked for the biological activity in
filamentation assay in RPMI-1640 medium. Hyphae formation
was inhibited by one fraction. This partially purified fraction was
thus analyzed by GC-MS. GC showed several peaks (Fig. 1) which
were further examined by MS. The analysis of the results using
data system library (NIST 49 K) indicated the presence of short
chain fatty acids: caproic acid (C6:0) at 3.98 min peak, caprylic
acid (C8:0) at 5.32 min peak and capric acid (C10:0) at 6.64 min
peak. Additionally, peak at 5.13 min was identified as 2-
phenylethanol.
Subsequently, commercially available standards of these fatty
acids and 2-phenylethanol were compared with the active fraction
for their retention times and mass spectra. Commercial com-
pounds exhibited similar retention times and the same fragmen-
tation patterns as compounds found in the S. boulardii extract,
confirming the presence of caproic acid (6:0), caprylic acid (8:0),
capric acid (10:0) and 2-phenylethanol in its active fraction
(Fig. S1).
To further confirm the identification of compounds, the active
fraction was analyzed by ESI-MS system, which provides a
minimal fragmentation of the analyzed sample during ionization.
The negative ionisation analysis showed the appearance of
molecular ions at m/z 115.076, 143.107 and 171.138 (Fig. 2).
The broader m/z window 100–1000 m/z is included in Fig. S2.
The m/z values for detected ions were the same as calulated from
the formulas of monoisotopic caproic (C6:0), caprylic (C8:0) and
capric (C10:0) acids ions [M–H]
2 which are 115.076, 143.107 and
171.139, respectively. The relatively low abundance of peak at m/z
115.076 results not only from the low concentration of caproic
acid (C6:0) in the sample but also from a decrease in sensitivity of
the Bruker micrOTOF-Q spectrometer in the range of m/z close
to 100 Da. Additionally ESI-MS spectra were obtained for
standards of caprilic (Fig. S3) and capric acids (Fig. S4). The peaks
of [M–H]- ions were observed in both cases and the fragmentation
in ion source was not detected. 2-Phenylethanol was not detected
in ESI-MS analysis, because ionization of this compound in ESI
experiment is poor.
The result confirmed the presence of three fatty acids with 6-, 8-
and 10-carbon in chain length in the active fraction.
S. boulardii extract and its active fraction were screened for the
presence of trans,trans-farnesol, which has been previously shown
to have similar activity as the compounds secreted by S. boulardii.
However, this molecule was not detected by GC-MS analysis; this
is consistent with our previous UPLC based data that farnesol
could not be responsible for S. boulardii extract activity [26]. At the
first sight there are structural similarities of capric acid with
farnesol having common biological activities (e.i. reduced hyphae
formation and repression of HWP1). In the same time there are
substantial differences in the chemical character. As we show, two
carbon difference in aliphatic chain length may significantly
influence biological activity. Carboxylic acid is much more
amphiphatic than farnesol with hydroxyl group. Finally, saturated
aliphatic chain is less rigid than unsaturated found in farnesol.
Figure 1. GC-MS analysis of active fraction separated from S.
boulardii extract. Peak at 3.98 min corresponds to presence of caproic
acid (C6:0), peak at 5.13 min to 2-phenylethanol, peak at 5.32 min to
caprylic acid (C8:0), peak at 6.64 min to capric acid (C10:0).
doi:10.1371/journal.pone.0012050.g001
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difficult to judge if the molecular mechanisms of action are
common.
To calculate the amounts of fatty acids and 2-phenylethanol in
the extract, the area of UPLC chromatogram peak of known
concentration of each commercially available pure standards was
compared with corresponding peaks present in S. boulardii extract.
UPLC analysis of extract showed peaks consistent with the
retention time of peaks for indicated compounds (Fig. 3),
additionally confirming that these compounds are secreated by
S. boulardii. Calculation revealed that 160 mgo fS. boulardii extract
contains at the most 37.8 mg of caproic acid (C6:0), 17.9 mgo f
caprylic acid (C8:0), 45.3 mg of capric acid (C10:0) and 4.2 mgo f
2-phenylethanol. These concentrations of tested compounds were
used in further experiments.
Capric acid (10:0) has been shown to kill C. albicans at very high
concentration (10 mM=1720 mg/ml) however it was able to
inhibit fungal growth at a concentration of 2.5 mM (430 mg/ml)
[21]. To exclude the possible killing effect on fungal cells by the
concentrations of identified fatty acids used in our study, the
viability test was performed. None of the tested compounds alone
inhibited C. albicans growth at concentrations which are present in
160 mg/ml of S. boulardii extract (the highest amount used in the
experiments).
Effect of the compounds on C. albicans filamentation
In order to determine whether the free fatty acids and 2-
phenylethanol are responsible for the inhibition of C. albicans
hyphae formation, the activity of each pure compound was
compared with the activity of S. boulardii extract. It is commonly
known that acidic pH can strongly inhibit filamentation of C.
albicans [27]. Fatty acids used in biological activity assay could
lower the pH of the medium so each sample was checked for the
pH value before the experiments. It was found that the pH of
RPMI-1640 (pH 7.5) was not affected by the addition of each
compound at tested concentrations.
Under the tested conditions, the capric acid (C10:0) alone
showed an inhibitory activity against hyphae formation compara-
ble to the S. boulardii extract alone (Fig. 4, left panel), as shown by
ratio of cells in yeast form compared to that with formed germ
tubes after 2 h of incubation. Caprylic acid (C8:0) had only a slight
effect on filamentation while caproic acid (C6:0) did not exhibit
any inhibitory action against C. albicans germ tube formation (data
not shown).
Inhibition of hyphae formation in C. albicans was previously
shown by fatty acids isolated from whey cream, mainly lauric acid,
myristoleic acid, palmitoleic acid, linoleic acid and arachidonic
acid [22]. The authors claimed that also capric acid (C10:0) was
effective, though they did not isolate it.
2-Phenylethanol was not found to affect the yeast-to-hyphae
switch even at concentrations which were previously reported to
inhibit C. albicans morphological transition [17]. This discrepancy
may be due to a different experimental model of hyphae formation
assay or to different susceptibility of C. albicans strains used in
study. A mixture of all tested compounds did not show stronger
effect than capric acid (C10:0) alone. This suggests that there is no
synergy between the tested molecules and capric acid (C10:0) is
responsible for the observed inhibition of C. albicans filamentation.
After 24 h of incubation in the presence of tested compounds at
concentrations that do not affect cell growth, C. albicans reached
similar density in all samples (Fig. 4, right panel). While control
and 2-phenylethanol-treated culture contained a dense network of
Figure 3. UPLC chromatograms of 2-phenylethanol and fatty
acids as compared with S. boulardii extract monitored at
220 nm. Solid line represents 96 mgo fS. boulardii extract, dashed
line 5.1 mg of 2-phenylethanol, dotted line 17.4 mg of caproic acid
(C6:0), dash-dot-dot line 21.4 mg of caprylic acid (C8:0), dash-dot line
25.8 mg of capric acid (C10:0).
doi:10.1371/journal.pone.0012050.g003
Figure 2. ESI-MS pattern of active fraction showing ions at m/z 115.076, 143.107 and 171.138.
doi:10.1371/journal.pone.0012050.g002
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present in samples with S. boulardii extract, capric acid (C10:0) and
mixture of all compounds. Caprylic acid (C8:0) treated sample
contained some long filaments with considerable number of the
cells existing in yeast form pointing to a weaker activity of this acid.
Effect of the compounds on C. albicans adhesion and
biofilm formation
To determine if the fatty acids and 2-phenylethanol are also
responsible for the reduction of C. albicans adherence, commercial
compounds were assayed in adhesion test and compared with S.
boulardii extract activity. The extract reduced the ability of C.
albicans cells to adhere by about 78% (Fig. 5 B) while capric acid
(C10:0) caused only 36% reduction (Fig. 5 E), similar to that found
in the sample treated with mixture of all tested compounds (Fig. 5
G). This result indicates that the extract contains, apart from
capric acid (C10:0), other as yet unidentified molecule/s which
inhibit C. albicans adherence. Caproic acid (C6:0), caprylic acid
(C8:0) and 2-phenylethanol did not have any effect on C. albicans
adhesion (Fig. 5 C, D, F).
Adhesion subsequently leads to biofilm formation. Since capric
acid (C10:0) inhibited adhesion it could also reduce biofilm
formation. Indeed, the inhibitory effect of capric acid (C10:0) was
maintained after 48 h of incubation. The level of biofilm in C.
albicans sample treated with this fatty acid reached only 0.7460.16
arbitrary OD units, while values for control sample reached
2.5460.10, as measured by the intensity of crystal violet staining.
Figure 4. C. albicans morphology incubated for 2 h (left panel) and 24 h (right panel) in RPMI-1640 at 37uC in the presence of the
compounds. Control sample contained 1% methanol, other samples contained 160 mg/ml of S. boulardii extract, 17.9 mg/ml of caprylic acid (C8:0),
45.3 mg/ml of capric acid (C10:0) or 4.2 mg/ml of 2-phenylethanol. MIX – mixture of all the compounds at concentrations indicated above. Bar, 10 mm.
doi:10.1371/journal.pone.0012050.g004
Figure 5. Effect of the compounds on C. albicans adhesion. (A)
control sample with 1% methanol, (B) 160 mg/ml of S. boulardii extract,
(C) 37.8 mg/ml of caproic acid (C6:0), (D) 17.9 mg/ml of caprylic acid
(C8:0), (E) 45.3 mg/ml of capric acid (C10:0), (F) 4.2 mg/ml of 2-
phenylethanol, (G) mixture of all these compounds at concentrations
indicated above. Statistical analysis was performed using paired
Student t-test. P values ,0.05 were considered significant. Double
stars 0.001,P,0.01, triple stars P,0.001.
doi:10.1371/journal.pone.0012050.g005
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0.1760.04 (data not shown).
Effect of capric acid on C. albicans gene expression
Since the most active molecule produced by S. boulardii
inhibiting filamentation and partially also C. albicans adhesion is
capric acid (C10:0), we analyzed changes of chosen gene
expression levels in C. albicans cells treated with capric acid
(C10:0) and S. boulardii extract. The genes were chosen for their
implication in virulence of C. albicans, like hyphae formation
(HWP1, EFG1, HST7, CRK1, BIG1), adhesion process (HWP1,
EFG1, CSH1, BIG1), maintenance of cell wall integrity during
growth and morphogenesis (CHT3) or other features involved in its
pathogenicity (INO1).
The expression of genes is shown as relative values referred to
the untreated control that was set to one. Significant changes in
expression were found for three genes (Fig. 6). Both S. boulardii
extract and capric acid (C10:0) decreased the expression of HWP1
gene encoding a hyphal wall protein involved in adhesion and
biofilm formation [28,29]. This corresponded very well to
observed changes in morphology and adherence of C. albicans
cells treated with the two agents. Capric acid (C10:0) reduced
HWP1 transcript level 8 times more than S. boulardii extract, which
contains many other compounds (UPLC, GCMS data, not shown)
that may have an effect opposite to that of capric acid (C10:0).
Decreased expression of hyphae specific gene HWP1 was also
previously detected after treatment with farnesol [30]. HWP1 is a
downstream component of cAMP-PKA dependent pathway and is
positively regulated by EFG1, but its expression is independent of
the MAP kinase cascade, the second well-known pathway
implicated in hyphae formation [11,31]. Since capric acid
(C10:0) decreased the expression of HWP1, it is possible that it
inhibits the Efg1-dependent gene induction pathway. However,
HWP1 expression is also controled by TUP1 and RBF1, negative
and positive regulators of hyphal development, respectively
[12,31].
C. albicans cells treated with S. boulardii extract and capric acid
(C10:0) showed a reduced level of INO1 (Fig. 6), which is required
for the synthesis of phospholipomannan, a GPI-anchored
glycolipid on C. albicans cell surface important for its virulence
[32]. As previously reported, INO1 was upregulated in drug-
resistant C. albicans strains [33] and farnesol strongly decreased its
expression in C. albicans biofilm [34].
Exposure to both S. boulardii extract and capric acid (C10:0) also
reduced the expression of CSH1 that encodes a protein associated
with the cell surface hydrophobicity and believed to be involved in
C. albicans virulence, including inhibition of adhesion to fibronectin
[35,36]. Decreased expression of CSH1 is consistent with the
observed inhibitory effect on adhesion and biofilm formation by C.
albicans (Fig. 6). Reduction of CSH1 expression was also previously
found for farnesol treated biofilm of C. albicans [34].
The expression of other tested genes was not significantly
changed after exposure to S. boulardii extract.
In conclusion, the results presented herein provide new evidence
that S. boulardii secretes into the medium fatty acids and 2-
phenylethanol, among which capric acid (C10:0) is the most
effective in inhibiting essential virulence factors of C. albicans,
especially morphological transition and partly adhesion as well as
biofilm formation. Capric acid (C10:0) also reduced expression of
HWP1, INO1 and CSH1 genes related to C. albicans pathogenicity.
Although capric acid (C10:0) is a major player reducing
morphological transformation, there is a clear difference in
biological C. albicans response after treatment with pure compound
and extract from S. boulardii. Thus, to explain myriad of benefits
coming from S. boulardii administration, it is necessary to explore
the activity and interactions of other compounds secreted by this
organism.
Materials and Methods
Strains and growth conditions
C. albicans strain SC5314 [37] was used in this study.
Lyophilized S. boulardii culture was supplied by Biocodex, Ultra-
LevureH (Gentilly, France). An isolated colony of each strain was
inoculated into 5 ml of Yeast Nitrogen Base broth (YNB pH 5.5)
(Difco Laboratories, Detroit, Mich.) containing 2% D-glucose, and
incubated overnight at 30uC. One hundred ml of such pre-culture
was inoculated into 5 ml of YNB, incubated for 24 h at 30uC and
used for all experiments.
Preparation of S. boulardii extract
S. boulardii extract was prepared from culture filtrate as
described previously [26]. Briefly, two liters of 24 h culture of S.
boulardii were centrifuged at 3.0006g for 10 min. The supernatant
was decanted and extracted with one-fifth volume of ethyl acetate
with changes of ethyl acetate every half an hour of extraction. The
ethyl acetate was removed on a rotary evaporator and the residue
was resuspended in methanol to give the final concentration of
48 mg/ml of residue in the stock sample. The extract was diluted
to give the final concentration of 160 mg/ml in each sample. The
concentration of methanol in a sample was never .1%.
Fractionation of S. boulardii extract
The S. boulardii extract was fractionated on a silica plate
containing a fluorescent indicator with glass bottom
(20 cm620 cm60.2 cm, Macherey Nagel, Du ¨ren, Germany)
using a chloroform/methanol (20:1, v/v) mobile phase in a
vertical glass chamber. Then the plate was air dried and observed
under 254 nm. The silica on the plate was divided into 7 fractions
by UV active bands and scraped into separate tubes. It was
subsequently washed 3 times with methanol. The volume of
collected methanol from each fraction was reduced using rotary
evaporator (Heidolph, Schwabach, Germany) to concentrate
samples and analyzed for the biological activity in hyphae
Figure 6. Relative expression of 3 mRNAs of C. albicans cells
treated with 45.3 mg/ml of capric acid (C10:0) and 160 mg/ml of
S. boulardii extract. Statistical analysis was performed using one
sample Student t-test. P values ,0.05 were considered significant.
Single stars denote 0.01,P,0.05, double stars 0.001,P,0.01, triple
stars P,0.001.
doi:10.1371/journal.pone.0012050.g006
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determination of chemical structures of relevant compounds.
GC-MS analysis
Active fraction and S. boulardii extract was analysed by Hewlett-
Packard 5890 II coupled with Hewlett-Packard HP-5971 A
(Hewlett-Packard, Palo Alto, CA) mass selective detector with Elite
5 MS column (25 m60.2 mm60.33 mm) in a splitless mode. The
oven temperature was programmed from 70 to 290uC and the
transfer line was heated at 280uC. Helium carrier gas had a flow of
1 ml/min. The mass spectrometer was operated in the electron
impact mode at 70 eV, scanning the range of 35–550 m/z in a full
scan acquisition mode. The identification of compounds was
achieved by comparing the GC retention times and mass spectra
with those of pure of caproic acid (C6:0), caprylic acid (C8:0),
capric acid (C10:0) and 2-phenylethanol standards (Sigma-
Aldrich, St. Louis, Mo). All mass spectra were also compared
with the data system library (NIST 49 K).
ESI-MS analysis
High-resolution ESI-MS spectra were obtained on a Bruker
micrOTOF-Q spectrometer (Bruker Daltonik, Bremen, Ger-
many), equipped with Apollo II electrospray ionization source
with ion funnel, operated in the negative ion mode. The sample in
methanol (0.05 mg/ml) was infused at a flow rate of 3 ml/min.
The potential between the spray needle and the orifice was set to
4.5 kV. Before each run the instrument was calibrated externally
with the Tunemix
TM mixture (Bruker Daltonik, Bremen, Ger-
many) in quadratic regression mode.
Ultra performance liquid chromatography (UPLC)
UPLC analysis was performed using a Waters ACQUITY
UPLC Systems with a PDA detector with the column (length 5 cm
with 1.7 small-particle chemistries; Waters Corp., Milford, Mass.).
Commercial fatty acids and 2-phenylethanol (Sigma-Aldrich) were
diluted in methanol. 17.4 mg of caproic acid (C6:0), 21.4 mgo f
caprylic acid (C8:0), 25.8 mg of capric acid (C10:0), 5.1 mgo f2 -
phenylethanol and 96 mgo fS. boulardii extract were injected into
UPLC column. The elution was carried out with methanol
gradient, starting with 10% methanol and reaching 100% in
8 min and being run for another 4 min. The chromatograms of all
standard compounds were monitored at 220 nm and compared
with the chromatogram obtained for S. boulardii extract. The
amount of fatty acids and 2-phenylethanol in S. boulardii extract
was calculated by comparing areas under corresponding chro-
matogram peaks.
Hyphae formation assay
Two mlo fC. albicans culture was added to every 0.5 ml of
RPMI-1640 medium, containing 160 mg/ml of S. boulardii extract
or one of the S. boulardii fractions isolated by TLC plate
fractionation. In different experiment the 37.8 mg/ml caproic
acid, 17.9 mg/ml of caprolic acid, 45.3 mg/ml of capric acid and
4.2 mg/ml 2-phenylethanol (Sigma-Aldrich) were used. All diluted
in methanol; the concentration of methanol in a sample was never
.1%. As a control, RPMI-1640 with 1% of methanol was used.
The assay was carried out in a 24-well plate (Nunc, Roskilde,
Denmark). After 2 and 24 h of incubation at 37uC the wells were
examined under an inverted microscope Olympus CKX41 and
photographed using the ARTCAM-300MI camera (Olympus,
Tokyo, Japan) with 406 magnification. Inactive fractions or
control contained 2–5% of yeast cells, while active fractions
contained 50–100% of yeast cells.
Adhesion assay
C. albicans adhesion assay was performed as described previously
(Krasowska et al., 2009). Briefly, 50 mlo fC. albicans culture
(5610
6 cells/ml) and 50 ml of RPMI-1640 were added to each
well together with the appropriate amount of S. boulardii extract
and fatty acids or 2-phenylethanol. The wells containing C. albicans
culture only in RPMI-1640 with 1% methanol were used as
control. After 1 hour incubation at 37uC nonadherent cells were
removed by three washes with phosphate buffer saline pH 7.4.
Adherent cells were stained with 0.1% crystal-violet for 5 min and
again washed three times with phosphate buffer saline pH 7.4.
Next, 150 ml of isopropanol-0.04 M HCl and 50 ml of 0.25% SDS
were added to each well to resolubilize crystal violet. The
absorbance of each well was measured using a microplate reader
UVM340 at A590 (Asys Hitech GmbH, Eugendorf, Austria).
Assays were carried out three times in five replicates.
In case of biofilm formation, the experiment was performed as
described above, but the plate was incubated for 48 h at 37uC.
Gene expression assay
After 24 h incubation at 30uC C. albicans cells were harvested,
washed with phosphate buffer saline and diluted in 18 ml RPMI-
1640 medium to give a final concentration of 5610
6 cells/ml.
Samples contained 6 ml of such C. albicans culture and 160 mg/ml
of S. boulardii extract or 45.3 mg/ml capric acid (C10:0) or only 1%
methanol for control. All samples were incubated at 37uC for 2 h
and then centrifuged at 10006g for 5 min. Total RNA was
isolated from obtained pellets using Total RNA Mini isolation kit
(A&A Biotechnology, Poland) following manufacturer’s instruc-
tions. Subsequently, the isolated RNA was digested with DNase I,
RNase-free (Fermentas International, Burlington, Canada). cDNA
synthesis was performed using High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA) following
manufacturer’s instructions. Primers for real-time PCR were
designed using LightCycler Probe Design Software 2.0 (Table 1).
Actin gene was used as endogenous control. The relative
concentration of each transcript was determined using RealTime
2xPCR Master Mix SYBR B (A&A Biotechnology, Gdansk,
Poland) on Light Cycler 2.0 (Roche, Indianapolis, IN). Each PCR
protocol consisted of a primary denaturation step at 95uC for
20 sec, followed by 30 cycles of denaturation at 95uC for 20 sec,
annealing at 45uC and extension at 72uC for 15 sec. Each product
was checked for its specificity in melting curve analyses and
efficiency of the amplification was verified with standard curves for
every gene. Results were analyzed by LightCycler Software 4.0.
Each assay was repeated three times for separately isolated RNA.
Table 1. Sequences of primers used for RT-PCR.
Forward primer Reverse primer
ACT1 TTTAAGAATTGATTTGGCT GAAGATTGAGAAGAAGTTT
BIG1 TTATTCGTCCTACTAGCAT CATATTTGTCACCGAAGTAA
CHT3 GTATTTCCAAATCCAGTTC GTCAATATTTGATAAGTCG
CRK1 CAGGTGGAATGGATACTTA GTACTATTTGAAGTCAACG
CSH1 AAATGGTAAATCTGAAGAG CCAATATATCTTGCCAATC
HST7 TCATCAGCTTCTTCTATAC TATTGAGGAAATGACAGTT
HWP1 ATTCCAAATATTCCAACTG TTCTGAAGTGGTAGCTAAA
INO1 TTCAGAATTAATGTTGGGT TTCTTTCAAATCTTAATTCGT
EFG1 GCCTTATAACTACATGTTC TGGTAATAGTTTCCTTGAG
doi:10.1371/journal.pone.0012050.t001
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Statistical analysis was performed using paired Student t-test,
with Bonferroni correction or one sample Student t-test. P
values ,0.05 were considered significant. Single stars denote
0.01,P,0.05, double stars 0.001,P,0.01, triple stars P,0.001.
Supporting Information
Figure S1 The ESI/MS spectrum of active fraction in 100-
1000 m/z window.
Found at: doi:10.1371/journal.pone.0012050.s001 (0.27 MB
PNG)
Figure S2 The comparison of fragmentation pattern and
retention times of commercially available standards with com-
pounds being in active fraction.
Found at: doi:10.1371/journal.pone.0012050.s002 (0.36 MB
PNG)
Figure S3 ESI/MS spectrum of caprylic acid (C8:0) standard.
Found at: doi:10.1371/journal.pone.0012050.s003 (0.36 MB
PNG)
Figure S4 ESI/MS spectrum of capric acid (C10:0) standard.
Found at: doi:10.1371/journal.pone.0012050.s004 (0.31 MB
PNG)
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